Incyte Corporation (INCY)

$66.12

+0.75

(+1.15%)▲

Market is closed - opens 7 PM, 14 Oct 2024

Performance

  • $65.38
    $66.21
    $66.12
    downward going graph

    1.13%

    Downside

    Day's Volatility :1.25%

    Upside

    0.13%

    downward going graph
  • $50.27
    $70.36
    $66.12
    downward going graph

    23.97%

    Downside

    52 Weeks Volatility :28.55%

    Upside

    6.03%

    downward going graph

Returns

PeriodIncyte CorporationSector (Health Care)S&P500
3 Months
2.91%
3.8%
3.6%
6 Months
23.75%
10.8%
13.5%
1 Year
14.77%
18.2%
34.4%
3 Years
2.96%
22.6%
33.3%

Highlights

Market Capitalization
12.7B
Book Value
$15.65
Earnings Per Share (EPS)
0.41
PE Ratio
161.27
PEG Ratio
0.56
Wall Street Target Price
73.95
Profit Margin
2.52%
Operating Margin TTM
-45.67%
Return On Assets TTM
0.39%
Return On Equity TTM
2.52%
Revenue TTM
3.9B
Revenue Per Share TTM
17.32
Quarterly Revenue Growth YOY
9.3%
Gross Profit TTM
1.6B
EBITDA
124.2M
Diluted Eps TTM
0.41
Quarterly Earnings Growth YOY
6.71
EPS Estimate Current Year
1.45
EPS Estimate Next Year
5.96
EPS Estimate Current Quarter
-1.55
EPS Estimate Next Quarter
1.48

Analyst Recommendation

Buy
    55%Buy
    44%Hold
    0
    0%Sell
Based on 29 Wall street analysts offering stock ratings for Incyte Corporation(by analysts ranked 0 to 5 stars)
Based on 29 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
16
Hold
13
12
11
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 11.84%

Current $66.12
Target $73.95

Company Financials

FY18Y/Y Change
Revenue
1.9B
↑ 22.5%
Net Income
109.5M
↓ 134.97%
Net Profit Margin
5.82%
↑ 26.2%
FY19Y/Y Change
Revenue
2.2B
↑ 14.71%
Net Income
446.9M
↑ 308.16%
Net Profit Margin
20.7%
↑ 14.88%
FY20Y/Y Change
Revenue
2.7B
↑ 23.53%
Net Income
-295.7M
↓ 166.17%
Net Profit Margin
-11.09%
↓ 31.79%
FY21Y/Y Change
Revenue
3.0B
↑ 11.98%
Net Income
948.6M
↓ 420.79%
Net Profit Margin
31.76%
↑ 42.85%
FY22Y/Y Change
Revenue
3.4B
↑ 13.67%
Net Income
340.7M
↓ 64.09%
Net Profit Margin
10.04%
↓ 21.72%
FY23Y/Y Change
Revenue
3.7B
↑ 8.87%
Net Income
597.6M
↑ 75.42%
Net Profit Margin
16.17%
↑ 6.13%
Q1 FY23Q/Q Change
Revenue
808.7M
↓ 12.74%
Net Income
21.7M
↓ 23.74%
Net Profit Margin
2.68%
↓ 0.39%
Q2 FY23Q/Q Change
Revenue
954.6M
↑ 18.05%
Net Income
203.5M
↑ 837.88%
Net Profit Margin
21.32%
↑ 18.64%
Q3 FY23Q/Q Change
Revenue
919.0M
↓ 3.73%
Net Income
171.3M
↓ 15.86%
Net Profit Margin
18.64%
↓ 2.68%
Q4 FY23Q/Q Change
Revenue
1.0B
↑ 10.26%
Net Income
201.1M
↑ 17.41%
Net Profit Margin
19.84%
↑ 1.2%
Q1 FY24Q/Q Change
Revenue
880.9M
↓ 13.07%
Net Income
169.5M
↓ 15.68%
Net Profit Margin
19.25%
↓ 0.59%
Q2 FY24Q/Q Change
Revenue
1.0B
↑ 18.49%
Net Income
-444.6M
↓ 362.23%
Net Profit Margin
-42.6%
↓ 61.85%
FY18Y/Y Change
Total Assets
2.6B
↑ 14.9%
Total Liabilities
719.8M
↑ 7.12%
FY19Y/Y Change
Total Assets
3.4B
↑ 29.52%
Total Liabilities
828.3M
↑ 15.08%
FY20Y/Y Change
Total Assets
3.6B
↑ 3.92%
Total Liabilities
949.7M
↑ 14.64%
FY21Y/Y Change
Total Assets
4.9B
↑ 38.54%
Total Liabilities
1.2B
↑ 22.5%
FY22Y/Y Change
Total Assets
5.8B
↑ 18.4%
Total Liabilities
1.5B
↑ 26.43%
FY23Y/Y Change
Total Assets
6.8B
↑ 16.11%
Total Liabilities
1.6B
↑ 8.25%
Q1 FY23Q/Q Change
Total Assets
5.8B
↓ 0.74%
Total Liabilities
1.3B
↓ 9.23%
Q2 FY23Q/Q Change
Total Assets
6.2B
↑ 7.08%
Total Liabilities
1.5B
↑ 9.93%
Q3 FY23Q/Q Change
Total Assets
6.4B
↑ 2.9%
Total Liabilities
1.5B
↓ 0.73%
Q4 FY23Q/Q Change
Total Assets
6.8B
↑ 6.17%
Total Liabilities
1.6B
↑ 9.3%
Q1 FY24Q/Q Change
Total Assets
7.1B
↑ 5.21%
Total Liabilities
1.7B
↑ 9.36%
Q2 FY24Q/Q Change
Total Assets
4.7B
↓ 34.67%
Total Liabilities
1.7B
↓ 4.4%
FY18Y/Y Change
Operating Cash Flow
336.2M
↓ 461.58%
Investing Cash Flow
-86.4M
↓ 75.31%
Financing Cash Flow
14.7M
↓ 97.88%
FY19Y/Y Change
Operating Cash Flow
710.7M
↑ 111.36%
Investing Cash Flow
-87.5M
↑ 1.19%
Financing Cash Flow
45.7M
↑ 211.87%
FY20Y/Y Change
Operating Cash Flow
-124.6M
↓ 117.53%
Investing Cash Flow
-269.0M
↑ 207.59%
Financing Cash Flow
71.7M
↑ 56.87%
FY21Y/Y Change
Operating Cash Flow
749.5M
↓ 701.52%
Investing Cash Flow
-207.7M
↓ 22.79%
Financing Cash Flow
6.2M
↓ 91.39%
FY22Y/Y Change
Operating Cash Flow
969.9M
↑ 29.41%
Investing Cash Flow
-78.5M
↓ 62.18%
Financing Cash Flow
-794.0K
↓ 112.86%
Q1 FY23Q/Q Change
Operating Cash Flow
-105.6M
↓ 137.23%
Investing Cash Flow
-28.6M
↑ 36.57%
Financing Cash Flow
4.0M
↓ 261.65%
Q2 FY23Q/Q Change
Operating Cash Flow
306.5M
↓ 390.26%
Investing Cash Flow
-7.4M
↓ 73.99%
Financing Cash Flow
12.9M
↑ 220.98%

Technicals Summary

Sell

Neutral

Buy

Incyte Corporation is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Incyte Corporation
Incyte Corporation
4.03%
23.75%
14.77%
2.96%
-14.64%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-11.94%
13.03%
20.97%
85.64%
232.53%
Novo Nordisk A/s
Novo Nordisk A/s
-12.38%
-3.12%
17.52%
138.65%
361.43%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
7.18%
92.5%
69.12%
39.45%
259.26%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.75%
21.23%
29.84%
165.64%
177.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Incyte Corporation
Incyte Corporation
161.27
161.27
0.56
1.45
0.03
0.0
NA
15.65
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.88
26.88
1.38
45.01
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.83
40.83
1.8
3.37
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.38
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.58
0.33
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Incyte Corporation
Incyte Corporation
Buy
$12.7B
-14.64%
161.27
2.52%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.1B
232.53%
26.88
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$523.9B
361.43%
40.83
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$36.5B
259.26%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$124.3B
177.5%
32.84
-4.74%

Insights on Incyte Corporation

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 880.88M → 1.04B (in $), with an average increase of 15.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 201.07M → -444.60M (in $), with an average decrease of 189.0% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.1% return, outperforming this stock by 54.3%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 39.4% return, outperforming this stock by 36.4%

Institutional Holdings

  • Baker Bros Advisors LP

    15.96%

  • BlackRock Inc

    11.09%

  • Vanguard Group Inc

    10.58%

  • Dodge & Cox

    7.93%

  • State Street Corp

    5.63%

  • Renaissance Technologies Corp

    2.71%

Company Information

incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.

Organization
Incyte Corporation
Employees
2524
CEO
Mr. Herve Hoppenot
Industry
Health Technology

Discover More

FAQs